1. Opening remarks……………………………………………Chair
2. Approval of January 17, 2018 P&T Committee Meeting minutes…………Chair
3. Pharmacy program update…………………………………………Alabama Medicaid
4. Opioid data and trends presentation………………..…ALM Health Systems Division
5. Oral presentations by manufacturers/manufacturers’ representatives
   (prior to each respective class review)
6. Pharmacotherapy class re-reviews………………University of Massachusetts
   Clinical Pharmacy Services
   • Eye, Ear, Nose and Throat Preparations-Antiallergic Agents – AHFS 520200
   • Eye, Ear, Nose and Throat Preparations -Antibacterials – AHFS 520404
   • Eye, Ear, Nose and Throat Preparations -Vasoconstrictors – AHFS 523200
   • Androgens – AHFS 680800
   • Centrally Acting Skeletal Muscle Relaxants – AHFS 122004
   • Direct-Acting Skeletal Muscle Relaxants – AHFS 122008
   • GABA-Derivative Skeletal Muscle Relaxants – AHFS 122012
   • Skeletal Muscle Relaxants, Miscellaneous – AHFS 122092
   • Opiate Agonists – AHFS 280808
   • Opiate Partial Agonists – AHFS 280812
   • Selective Serotonin Agonists – AHFS 283228
   • Antiemetics, Antihistamines – AHFS 562208
   • Antiemetics, 5-HT3 Receptor Antagonists – AHFS 562220
   • Antiemetics, Neurokinin-1 Receptor Antagonists – AHFS 562232
   • Antiemetics, Miscellaneous – AHFS 562292
   • Proton-Pump Inhibitors – AHFS 562836
7. Pharmacotherapy class review
   • Complement Inhibitors for HAE – AHFS 923200
8. Results of voting announced……………………………………………………………Chair
9. Next meeting date
   • August 8, 2018
   • November 7, 2018
10. Adjourn